Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome wide CRISPR screen for Sorafenib resistance in MOLM13 and MV411 cells using Y. Kosuke library

ABSTRACT: MOLM13 or MV411 cells were generated to express Cas9, infected with CRISPR library (Tzelepis et al 2016) , selected for puromycin resistance and exposed to Sorafenib (50nM), Crenolanib (20nM) or vehicle, DMSO. Cells were collected at time 0 (post puromycin selection), day 7 and 14 for Sorafenib as well as 14 and 21 for Crenolanib. DNA was extracted and sgRNA barcodes were amplified. The resulting PCR library was deep sequenced using the Illumina HiSeq 2500 using 6 samples per lane.

ORGANISM(S): Homo sapiens

PROVIDER: GSE138343 | GEO | 2021/05/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

Project description:MOLM13 cells were infected with CRISPR/Cas9 library, selected for puromycn resistance for integration events and exposed to Venetoclax or vehicle, DMSO, at 1microMolar concentrations. Cells were collected at time 0 (post puromycin selection), day 7 and 14 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Hiseq using 6 samples per lane.

2019-04-30 | GSE130412 | GEO

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Brunello library

2019-04-30 | GSE130413 | GEO

Genome wide CRISPR screen for Sorafenib resistance in MOLM13 and MV411 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Sorafenib resistance in MOLM13 and MV411 cells using Y. Kosuke library

| PRJNA575535 | ENA

Genome wide CRISPR screen for BET inhibitor resisatnce in OCI-AML2 cells using Y. Kosuke library

Project description:OCI-AML2 BETi-naive or JQ1 resistant cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to JQ1/CPI-0610 or vehicle, DMSO, at 200nanoMolar for JQ1 and 500nanoMolar CPI-0610 concentrations. Cells were collected at time 0 (post puromycin selection), day 14 JQ1 and 21 CPI-0610 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Hiseq using 6 samples per lane.

2023-10-13 | GSE159689 | GEO

Effect of pyrvinium pamoate on transcriptome and signaling pathways in FLT3-ITD acute leukemic cell line Molm13

Project description:To identify molecular effects of a classical anthelmintic pyrvinium pamoate(PP), we applied gene expression profiling in human acute leukemic cell line FLT3-ITD+ Molm13 using Whole Transcriptome Shotgun Sequencing (RNA-seq) after 6 h treatment with 50nM or 100nM pyrvinium. We got 94 and 219 differentially expressed genes (DEGs) compared with the control group, respectively. Among 94 DEGs in the 50nM pyrvinium group, 62 were upregulated and 32 were downregulated and corresponded 162 upregulated and 57 downregulated DEGs in the 100nM pyrvinium group.

2021-12-29 | GSE153854 | GEO

Genome wide CRISPR screen for CG-806 resistance in OCI-LY3 cells using Y. Kosuke library

Project description:OCI-LY3 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed to CG-806 or vehicle, DMSO, at 1 microMolar concentrations. Cells were collected at time 0 (post puromycin selection) and day 7. DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using highthroughput Illumina platform Novaseq 6000.

2023-05-04 | GSE174766 | GEO

Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Venetoclax resisatnce in MOLM13 cells using Y. Kosuke library

| PRJNA540211 | ENA

Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

Project description:Genome wide CRISPR screen for Trametinib sensitivity in resistant MOLM13 cells using Y. Kosuke library

| PRJNA984725 | ENA

In vivo screen identifies LXR agonism potentiates sorafenib killing of hepatocellular carcinoma

Project description:Background & Aims: Existing drug therapies for hepatocellular carcinoma (HCC), including sorafenib, extend patient survival by only three months. We sought to identify novel druggable targets for use in combination with sorafenib to increase its efficacy. Methods: We implemented an in vivo genetic screening paradigm utilizing a library of 43 genes-of-interest expressed in the context of repopulation of the injured livers of Fumarylacetoacetate Hydrolase-deficient (Fah-/-) mice, which led to highly penetrant HCC. We treated mice with vehicle or sorafenib, then determined the genetic drivers of each tumor from the library. Liver X Receptor alpha (LXRalpha) emerged as a potential target. To examine LXRalpha agonism in combination with sorafenib treatment, we added varying concentrations of sorafenib and LXRalpha agonist drugs to HCC cell lines. To elucidate the mechanism of tumor death, we performed transcriptomic analysis. Results: Fah-/- mice injected with the screening library developed HCC tumor clones containing Myc cDNA plus various other cDNAs. Treatment with sorafenib resulted in sorafenib-resistant HCCs that were significantly depleted in Nr1h3 cDNA, encoding LXRalpha, suggesting that LXRalpha activation is incompatible with tumor growth in the presence of sorafenib treatment in vivo. Combination treatment using sorafenib and LXR agonist drugs in multiple HCC cell lines led to enhanced cell death as compared to monotherapy, due to reduced expression of cell cycle regulators and increased expression of genes associated with apoptosis. Combination therapy also enhanced cell death in a sorafenib-resistant primary human HCC cell line. Conclusions: We have completed a novel drug resistance screen in vivo, and identified that LXR agonism potentiates the efficacy of sorafenib in treating HCC.

2020-05-29 | GSE151412 | GEO

Genome wide CRISPR screen for Venetoclax plus Ruxolitinib combination resistance in OCI-AML2 cells using Y. Kosuke library

Project description:30 million OCI-AML2 cells were infected with CRISPR/Cas9 library, selected for puromycin resistance for integration events and exposed DMSO, venetoclax (0.5 uM) or venetoclax (0.1 uM) plus ruxolitinib (1 uM). Cells were collected at day 14 and 21 , DNA was extracted and sgRNA barcodes were amplified. PCR library was deep sequenced using Novaseq 6000 high throughput Illumina platform.

2023-06-30 | GSE216087 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data